About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT05174533

Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia

Schizophrenia is a psychiatric disorder, affecting 600,000 patients in France. Patients with schizophrenia have life expectancy decrease from 10 to 20 years because of cardiovascular death. Cardiovasc...

Lead sponsor: Université de Reims Champagne-Ardenne•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

CURRS Université de Reims Champagne-Ardenne

CONTACT

0326918822 [email protected]

Coralie BARBE, MD

CONTACT

0326918822 [email protected]

Sponsors

Lead Sponsor

Université de Reims Champagne-Ardenne

The aim of the study is to describe prevalence of cardiovascular disorders in patients aged 40 and more with schizophrenia.

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•male or female
•aged of 40 and more
•with schizophrenia
•agreeing to participate in the study

Related studies

RECRUITINGPhase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212 · Schizophrenia

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

NCT06003036 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

NCT05052853 · Prodromal Schizophrenia

RECRUITINGPhase 2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

NCT05240976 · Schizophrenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 1, 2022Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment50

Start dateJan 2022

Last updatedFeb 1, 2022

Condition

Locations shown

Epsmd de l'Aisne

Prémontré, Grand Est

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 1, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions